-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Initiates Coverage On Indivior Pharmaceuticals with Overweight Rating, Announces Price Target of $46

Benzinga·06/18/2026 12:49:34
Listen to the news
Barclays analyst Glen Santangelo initiates coverage on Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight rating and announces Price Target of $46.